to the fallopian tubes to relieve the pain of tubal occlusion performed with the use of local anaesthesia, with intravenous sedation and with general anaesthesia. ,-3 The doses of local anaesthetics used vary widely. Wc reported a significant reduction in narcotic requirement in the recovery period when etidocaine was applied to the fallopian tubes before occlusion during laparoscopy,3 ~c frequency of overnight stay in hospital was also significantly reduced.. The safety and effectiveness of etidocaine compared with other local anaesthetics used for this purpose have not been studied. We therefore designed a double-blind, randomized clinical trial to compare the clinical effectiveness of bupivacaine and etidocaine. The safety of topical application was evaluated by measuring the blood concentrations of the local anaesthetics along with their metabolites.
Methods
With the approval of our hospital human investigation committee, informed consent was obtained from 22 healthy outpatients having laparoscopic tubal occlusion under general anaesthesia. They were randomly assigned to one of two groups.
All patients received fentanyl 50 ~g and droperidol 1.25 mg IV followed by prcoxygenation and precurarization. Anaesthesia was then induced with thiamylal 5 mg.kg -l, followed by succinylcholine, 100 rag, to facilitate tracheal intubation. Anaesthesia was maintained with 50 per cent nitrous oxide and oxygen with 0.5-2 per cent isoflurane. Following induction, a heparinized cannula was placed in a vein in the forearm not used for IV infusion, and a baseline blood sample was obtained. Nitrous oxide was insufflated to create the operative pneumopcritoneum needed for the surgery.
Patients in Group E had one per cent etidocalne, 2 mg.kg -~, and patients in Group B had 0.75 per cent bupivacaine, 1.5 mg.kg-', applied to both fallopian tubes from uterus to fimbria. A 20 nil syringe containing the unknown local anaesthetic was attached to a Kiddy cannula and dripped onto the fallopian tube under direct vision via the laparoscope. We previously established the CAN J ANAESTH 1989 / 36:5 / ppSl0-514 FIGURE 1 Venous whole blood levels -SEM of etidoeaine 2 rag. kg-I [] and bupivaeaine 1.5 mg'kg-1 9 following intraabdominal, topical application during laparoscopy, n = 11 in each group.
clinical effectiveness of 1 per eem etidocaine 3 and selected 0.75 per cent bupivacaine to obtain its maximum effect. Numbered syringes were prepared by one of the authors (AFV) according to the patient's weight. A 50 kg patient would require 10 ml of either drug in the syringe thereby precluding recognition of the solution and assuring double-blindness of surgical and anaesthetic personnel. The application of the unknown local anaesthetic was completed prior to tubal occlusion with Falope bands. At l, 3, 6, 10, 15, 30, 60 and 120 min after application, 2 ml samples of venous blood were drawn.
Whole blood was analyzed in triplicate by highpressure liquid chromatography (HPLC) for etidocaine and its metabolites, 2-amino-2'-butyroxylidide (ABX), 2-N-propylamino-2'butyroxylidide (PBX), and 2-Nethylamino-2'butyroxylidide (EBX) in Group E and for bupivacaine and its metabolite 2,6-pipecoloxylidide (PPX) in Group B. The samples were collected using nonheparinized syringes and immediately placed in a borate solution buffered to pH 9.5. The extraction was a two-step technique. The samples were first extracted into 10 ml of 30 per cent methylene chloride and then back extracted into 150 I~1 of 0.1 N HCI. All samples were frozen and later analyzed by HPLC using a reversedphase technique described by Kennedy et al. 4 Bupivacaine was used as the internal standard for the etidocaine and metabolite analyses, and etidoeaine as the internal standard for the bupivacalne and PPX analyses. Ultraviolet detection was used with a wavelength of 210 nm for maximum absorbance. Detection limits were etidocalne, 10 ng" ml-1; bupivacaine, 15 ng-ml-t; ABX, 5 ng" ml-l; PPX, 5 ng 9 ml-t; EBX, 5 ng. ml-l; and PBX, 5 ng" mi-u. Standard curves were constructed and validated daily; they were found to be linear, r 2 _--> 0.99, for all compounds of interest.
On arrival at the recovery room and at 0.5, 1 and 2 hr after termination of anaesthesia, the degree and site of pain, occurrence of nausea or vomiting, and medieation(s) administered were recorded by an anaesthetist (RMCK or BMM) blinded to the local anaesthetic used. Subjective abdominal pain was assessed by the anaesthetist by asking the same questions of each patient. "Are you comfortable?" With a positive response, the patient was then asked specifically, "Are you having any abdominal painT' If so, she would classify the pain as mild, moderate or severe. With a negative response to the first question, the specific follow-up question on abdominal pain was asked. Nausea and vomiting were evaluated as 0 = nil, 1 = nausea, and 2 = vomiting. A follow-up telephone call was made the next day to record persistent or new complications.
Data were analyzed for statistical significance using the Fisher exact probability test. Level of P --< .05 was considered statistically significant.
Results
The two groups were similar in age, weight, height, haematocrit and duration of operation. With Group E, the mean peak whole blood concentration (-+ SEM) was 501.8 -+ 71.3 ng" m]-l; with a range of 222-905 ng. ml-1 (Figure 1) . Corresponding values for Group B were 468.8 +-73.8 ng.m1-1 with a range of 191-1005 ng.ml -I. Mean peak concentrations occurred at 17.7 min (range 6-30 rain) with etidocaine and at 33.2 min (range 10-60 rain) with bupivacaine (Table I) . There were rapid, parallel increases in blood concentrations of both parent drugs during the fn'st 15 min. After 20 min, etidocaine levels began to decrease. Bupivaeaine levels reached a plateau from 20-60 rain before slowly declining. Blood concentrations of both drugs decayed at a similar rate (Figure 1) . The metabolic degradation products of etidoeaine, ABX, PBX, and EBX, were all present in the l-rain sample (Figure 2 ). The major metabolite of bupivacaine, PPX, did not consistently appear until the 60-rain sample (Figure 3) .
In the recovery room, pain was significantly less in Group E patients (Table II) No patient in either group had severe abdominal pain. Statistical significance P < 0.5 was reached for patients with no pain and moderate pain. Group E patients had less moderate pain and more patients reported no pain compared with group B (P < 0.5). Intravenous fentany150 Ixg in divided doses was necessary in one patient in Group B. An equal number of patients in both groups required oral analgesics (acetaminophen -oxycodone -acetaminophen [Percoset], or ibuprofen). Nausea occurred in three patients in Group E and in two patients in Group B. Vomiting occurred three times in two patients given bupivacaine. There was no significant difference in the incidence of nausea or vomiting in the two groups. At 24 hr one patient in each group complained of lower abdominal pain. FIGURE 3 Whole blood levels of bupivacaine 9 and ils major metabolitr 2,6-pipecoloxylidide (PPX) (3 following intraabdominal, topical application during laparoscopy. (Note the slow metabolism of parent drug bupivacaiue 9 to 2,6-pipecoloxylidide (PPX) 0.) n = 1 I.
Discussion
The intraoperative, intraperitoneal instillation of local anaesthetic agents to reduce pain has been used for many years. In 1950, Hanson and Hingson reported on seven patients who successfully underwent laparotomy with 500-1200 mg intrapcritoncal lidocaine, t The average duration of action was 45 rain. Cruikshank et al. found that nonconvulsive blood levels were attained with 1000 mg lidocaine in nonpregnant women having tubal occlu- sion under local anaesthesia supplemented with preoperative IV alphaprodine and diazepam. 2 For postpartum tubal ligation using the same analgesic and sedative drugs, subeonvulsive blood levels of lidocaine were also found when 500 mg lidocaine was used.2 Abdominal pain after laparoscopic tubal occlusion is severe in most patients, lasts from 4-6 hr, and may delay discharge from day surgery units. 3 Postoperative pain is more severe following laparoscopic sterilization than when diagnostic laparoscopy alone is performed, and for this reason studies of morbidity from laparoscopy patients having laparoscopic sterilization may be excluded. 5 Davis and Millar found that the laparoscopic sterilization patients have significantly more pain in the fu'st 4 hr after surgery than diagnostic laparoscopy patients (P < 0.02). 6 Etidocaine and bupivacaine were selected in the present study because extended duration of action is needed to provide postoperative comfort. However, both drugs have been implicated in cases of cardiac arrest following epidural and probably inadvertent intravascular administration. 7 Topical application avoids intravascular injection, but rapid absorption of the drug could still lead to toxic blood levels with convulsion and/or cardiac arrest. Although the clinical effectiveness of etidocainc one per cent and bupivacaine 0.5 per cent has been reported independently, blood analyses to verify the safety of intraabdominal instillation have not. 3,s
In the doses and concentrations that we compared, the patients in Group E complained of less severe abdominal pain than those in Group B. Although there were only 11 patients in each group, 84 spoken subjective pain assessments were made. Without valid doseresponse curves for each drug, the difference in effectiveness is not easily explained. Etidocaine differs from bupivacaine in physical properties, especially pKa and lipid solubility. At body pH etidocaine (pKa = 7.74) is less ionized than bupivacaine (pKa = 8.01). Etidoealne has a partition coefficient of 141 and is approximately five times as soluble in fat as bupivacaine. 2s Both drugs are 90-96 per cent protein bound. If more etidocaine is available to penetrate nervous tissue there may be more active ionized drug to account for superior pain relief.
The weight-normalized dose that produces seizures in rhesus monkeys is higher for etidocalne than for bupivacaine; etidocalne is therefore considered less toxic. 9 Plasma concentrations at seizure of these two drugs are similar. Having established an effective dose of etidocaine,3 we chose a dose of bupivacalne estimated to result in similar blood levels. To maximize the effectiveness of topical bupivacaine, the highest concentration was chosen. The similar peak blood concentrations may be attributable to the higher lipid solubility and more rapid metabolism of etidocaine. A high metabolite concentralion would imply greater safety for system toxicity by reducing the concentration of parent drug.
The earliest peak concentration for etidocalne at six minutes and for bupivacalne at ten minutes demonstrated that drugs placed intraabdominally may be absorbed rapidly into the bloodstream. Close patient surveillance is necessary for one hour because the latest peak concentrations occurred at 30 rain for Group E and 60 min for Group B. The blood level of a local anaesthetic parent drug is altered by the rapidity of metabolites produced. Etidocaine has three metabolites which appear quickly, indicating rapid metabolism by the liver. The early appearance of ABX, PBX and EBX and the increase in concentration over time account for the decrease in etidocaine level. Similarly, bupivaeaine levels remained high throughout the study with a low metabolite level for PPX. It is believed that none of these metabolites adds to the toxicity of the parent drugs. Our doses avoided toxicity as confa'med by serial blood analyses. The mean peak blood concentration was one-quarter of the reported minimal convulsive level of 2 p,g. ml -~ in monkeys 9 and oneeighth of the medal plasma levels that caused convulsions in humans.l~ Reduction of etidocaine concentrations, and hence its safety, appears to be related to metabolism. There is a possibility that absorption may in part be into the portal circulation rather than systemic, but this study could not determine differential absorption. Wide variations were noted in the venous blood levels. For etidocaine the range was from 222 to 905 rig. m] -I , while bupivacalne values were 191 to 1005 ng-ml -I. Doubling the dose might achieve convulsive levels in some patients. These results do not apply to procedures carried out under local anaesthesia, because possible cumulative effects of additional local anaesthetic agent could reach a convulsive level.
In summary, topical application of either etidocalne or bupivacalne was a safe procedure in the dose and concentration used. Furthermore, intravascular injection is impossible with topical application. The venous blood concentrations of etidocaine and bupivacalne were similar, although quantitatively 33 per cent more etidocalne was applied. The doses used were effective, and peak blood concentrations were below toxic levels despite wide individual variation.
